Cascade Oncogenics, Inc.

Portland, OR 97201

SBIR Award Summary

Total Number of Awards 4
Total Value of Awards $0.0
First Award Date 09/01/93
Most Recent Award Date 09/30/97

Key Personnel

Last Name Name Awards Contact
Passavant Charles W Passavant 4

4 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/97 - 09/29/98

Through the support of a Phase I SBIR we have successfully demonstrated the use of a novel and innovative proprietary technology for the identification of genes under the transcriptional control of the tumor suppressor p53. This technology has several distinct advantages over current methods used in...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/96 - 09/29/97

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/95 - 09/30/95

The overall objective of this SBIR proposal is the isolation and characterization of previously unidentified gene sequences that may be under transcriptional control by the p53 tumor suppressor. Using a single primer-mediated amplification technology, Targeted Inverted Repeat Amplification (T...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/93 - 02/28/94

The Targeted Selected Cloning technique is an extremely simple mechanism for cloning specific genomic or cDNA fragments using only a single oligonucleotide primer in a single thermal replication cycle. Uniprime Corporation wishes to develop this method for commercial applications. The steps for Targeted Selected Cloning of a sequence of interest...